Ovarian Cancer | Specialty

OncLive News Network On Location: In Chicago Sunday, June 2

June 2nd 2019

OncLive News Network On Location: In Chicago Saturday, June 1

June 2nd 2019

Work Remains With Immunotherapy in Ovarian Cancer

June 1st 2019

Daphne B. Stewart, MD, discusses the progress that has been made with immunotherapy in ovarian cancer, provides insight into the focus on combination therapy with checkpoint inhibitors, and explains the impact of negative trials on the field.

Debate Continues Between Primary Debulking and Neoadjuvant Chemo in Advanced Ovarian Cancer

May 31st 2019

Stephen J. Lee, MD, discusses the trials that have added to existing controversies regarding the optimal management of patients with newly diagnosed advanced ovarian cancer and highlights best practices for deciding between the approaches.

Dr. Konecny on the Indications for PARP Inhibitors in Recurrent Ovarian Cancer

May 29th 2019

Gottfried E. Konecny, MD, associate professor of medicine, University of California, Los Angeles, discusses the indications for the FDA-approved PARP inhibitors in recurrent ovarian cancer.

Examining the Underpinnings of PARP Inhibition in Recurrent Ovarian Cancer

May 28th 2019

Gottfried E. Konecny, MD, shares the known aspects of PARP inhibition in recurrent ovarian cancer.

Dr. Sabbatini on Frontline Treatment of Newly Diagnosed Ovarian Cancer

May 24th 2019

Paul Sabbatini, MD, deputy physician-in-chief for clinical research, Memorial Sloan Kettering Cancer Center, discusses the frontline treatment of patients with newly diagnosed ovarian cancer.

Search Continues for Optimal HIPEC Use in Ovarian Cancer

May 24th 2019

Ernest S. Han, MD, PhD, FACOG, discusses the role of HIPEC in advanced ovarian cancer at the time of interval debulking, as well as anticipated research examining its use at time of primary debulking.

Dr. Konner on Preferred Platinum Doublets in Recurrent Ovarian Cancer

May 18th 2019

Jason A. Konner, MD, medical oncologist, Memorial Sloan Kettering Cancer, discusses preferred platinum doublet chemotherapies in the treatment of patients with recurrent ovarian cancer.

Dr. Zamarin Discusses Ongoing Work With Immunotherapy in Ovarian Cancer

May 15th 2019

Dmitriy Zamarin, MD, PhD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses ongoing work with immunotherapy in patients with advanced ovarian cancer.

Survival Gains Prompt Growing Emphasis on Fertility Preservation

May 13th 2019

Improved outcomes such as longer survival have increased interest among patients in pursuing fertility preservation options, and advances in techniques have made it possible for more patients to have children after treatment.

Dr. Leitao Discusses the Role of HIPEC in Advanced Ovarian Cancer

May 7th 2019

Mario M. Leitao Jr, MD, FACOG, FACS, fellowship director, gynecology service, director, Minimal Access and Robotic Surgery Program, Department of Surgery, Memorial Sloan Kettering Cancer Center, discusses the role of HIPEC in patients with advanced ovarian cancer.

Mirvetuximab Soravtansine Shows Benefit in Folate Receptor Alpha+ Ovarian Cancer

May 4th 2019

The antibody-drug conjugate mirvetuximab soravtansine demonstrated a favorable benefit-risk profile in a prespecified subset of patients with folate receptor alpha–positive ovarian cancer, following a comprehensive analysis of the phase III FORWARD I trial.

Dr. Sabbatini on Promising Therapies in Newly Diagnosed Ovarian Cancer

May 2nd 2019

Paul Sabbatini, MD, deputy physician-in-chief for clinical research, Memorial Sloan Kettering Cancer Center, discusses promising therapies in newly diagnosed ovarian cancer.

Dr. Zamarin on Priming Strategies in Ovarian Cancer

April 30th 2019

Dmitriy Zamarin, MD, PhD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses priming strategies in ovarian cancer.

Outlook in Treating Patients With Ovarian Cancer

April 29th 2019

Ongoing Research in Ovarian Cancer

April 29th 2019

I/O Combination Strategies in Ovarian Cancer

April 29th 2019

Rationale for Immunotherapy in Ovarian Cancer

April 29th 2019

Ovarian Cancer: Recurrence After PARP Inhibition

April 29th 2019